Vycellix

15 articles about Vycellix

• Vycellix Presents Proof-of-Concept Data for VY-UC Allogeneic Cell Therapy Platform at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting, Paris

  6/5/2023

  Vycellix, Inc. today announced that its founding Chairman & CEO, Evren Alici, M.D., Ph.D., presented pre-clinical, proof-of-concept results for the Company’s single-step approach to engineer allogeneic cells (VY-UC) at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting in Paris.

• Coeptis Therapeutics Partners with VyGen-Bio, Inc. to Co-develop Two Assets Designed to Improve the Treatment of CD38-Related Cancers

  8/19/2021

  Coeptis Therapeutics, Inc. today announced it has exercised its option to acquire ownership in two technology assets that target CD38 cancers from VyGen-Bio, Inc., a majority-owned subsidiary of Vycellix, Inc.

• Vycellix to Present at Upcoming Life Science Conferences

  3/23/2021

  Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that members of its executive leadership team are scheduled to present and moderate panel sessions at the following upcoming life science conferences this week

• Vycellix CEO to Present its Universal Cell Program (VY-UC) for Off-the-Shelf NK Cell Therapy at Allogeneic Cell Therapies Summit

  10/22/2020

  Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that its Chairman & CEO, Evren Alici, M.D., Ph.D., will present at the upcoming Allogeneic Cell Therapies Summit.

• Vycellix CEO to Present Next-Generation Universal Cell Platform to Optimize Allogeneic Cell Therapies at ‘Innate Killer Summit’

  8/10/2020

  VY-UC represents novel & simplified approach to design “off-the-shelf” therapies resolving the complexities & limitations of gene-editing to modulate self-recognition proteins TAMPA, Fla. & STOCKHOLM--( BUSINESS WIRE )-- Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that its Chairman & CEO, Evren Alici, M.D., Ph.D., will present at the

• 

  Vycellix and Avectas Join Forces to Address Cell-Based Therapy Limitations

  3/26/2020

  Specifically, they will be looking at ways to improve processes by speeding up and reducing the cost of manufacturing.

• Vycellix and Avectas Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies

  3/25/2020

  Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the companies have entered into a collaboration agreement to develop proprietary approaches for cell-based immunotherapeutic products. The companies will collaborate on the delivery of Vycellix's novel RNA immunomodulator VY-M using Avectas' cell

• Avectas and Vycellix Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies

  3/24/2020

  Avectas, a cell engineering technology business and Vycellix, Inc. an immuno-discovery cell & gene therapy company, today announced that the companies have entered into a collaboration agreement to develop proprietary approaches for cell-based immunotherapeutic products.  The companies will collaborate on the de

• Vycellix Founders Awarded Innovation Grant by Sweden’s Vinnova to Establish New World-Class Research Environment on Development of Next-Generation Natural Killer Cell-based Cancer Immunotherapy

  6/27/2019

  Vycellix included as collaborative partner within the Center’s research constellation of prestigious academic & industry partners

• Vycellix Announces Formation of Scientific Advisory Board

  6/25/2019

  Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, has appointed the inaugural members of its Scientific Advisory Board (SAB).

• 

  1Q2019 Life Science Growth Announcements

  4/18/2019

  In the first quarter of 2019, more than 30 life science companies* announced  expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.

• Vycellix CEO to Present Strategies for Enhancing Next-Generation NK Cell Cancer Therapy at Innate Killer Summit

  3/15/2019

  Vycellix™, Inc. today announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, will present at the Innate Killer Summit 2019 to be held in San Diego, March 20-21.

• 

  Sweden-Based Vycellix Opens U.S. HQ in Tampa

  2/22/2019

  The Vycellix team, which will initially include its senior executive and administrative staff, is scheduled to occupy the new space adjacent to the Moffitt Cancer Center in April.

• Cell & Gene Immunotherapy Biotech, Vycellix, to Establish Headquarters in Tampa

  2/21/2019

  Vycellix™, Inc. announced that the Company, founded by leading medical researchers at Sweden’s world renowned Karolinska Institutet, will establish its U.S. headquarters in Tampa, Florida.

• Vycellix And H. Lee Moffitt Cancer Center & Research Institute Announce A Collaborative Research Study To Evaluate Novel Product Candidates For Improving Adoptive Cell Immunotherapies For Cancer

  2/27/2017